Prognostic Value of metabolic parameters on Pretreatment F-18 FDG PET/CT in Patients with Advanced melanoma treated with Pembrolizumab

Conclusions: In this retrospective analysis of patients with advanced melanoma treated with the PD-1 antibody pembrolizumab, tumor burden on FDG PET was highly significantly correlated with OS. Tumor burden on PET may allow investigators to better stratify patients in clinical trials of new immunotherapeutic agents and help clinicians with treatment decisions for individual patients.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Sarcoma/ Melanoma Source Type: research